source
- Kodiak Sciences' eye disease drug matches Eylea in Phase 3, sending stock soaringKodiak Sciences reported that two of its eye‑disease candidates performed on par with aflibercept (Eylea) in a pivotal Phase 3 trial. The data suggest comparable efficacy in treating the targeted r…
- Merck signs $400 million deal with China’s SciBrunch for KRAS G12D preclinical candidateMerck & Co. announced a new partnership with Chinese biotech SciBrunch. The agreement includes a $400 million payment for a preclinical candidate that targets the KRAS G12D mutation. The KRAS G12D…